2015 BIO International Convention
CAMBRIDGE, MA - June 12, 2015 - MedVax Technologies, Inc. announces that its Chief Executive Officer, Robert Brooks, will be attending the BIO International Convention taking June 15-18 at the Pennsylvania Convention Center. The world's largest biotechnology gathering, the BIO Exhibition, allows exhibitors to reach high-level executives and influential decision makers. They attend BIO each year to discover new players in the industry. The event is an opportunity for participants to form partnerships and evaluate emerging technologies. This year's gathering will feature more than 1,700 exhibitors in approximately 160,000 square feet of space. Tom Brokaw will serve as keynote speaker. Attendees will get a glimpse into the journalist's mind listening to his thoughts on U.S. and world affairs. Wynton Marsalis will entertain attendees during a unique evening event featuring the legendary musician.
BIO International is the World's Largest Biotechnology Gathering
The world's largest Biotechnology event covers the wide spectrum of life science innovations and application areas. Among them, Drug discovery, nanotechnology, biofuels, genomics, and cell therapy. This year's convention will host thousands of organizations including leading biotech companies, top pharma companies, CROs, CMOs, and more than hundreds of institutions including major research labs and government agencies. The convention will be held in the Philadelphia metropolitican area - home to more than 1,200 companies, ranging from the largest multinational and international companies to fast growing firms.
About MedVax Technologies, Inc.
MedVax is a biopharmaceutical company discovering and commercializing cancer immunotherapy drugs. MedVax's portfolio includes: MX-225, an autologous P53 dendritic cell vaccine that completed two Phase IIa trials in Small Cell Lung Cancer (SCLC), and recurring breast cancer. The company is planning a Phase II SCLC combination trial with MX-225 and a PD-1 antibody and developing a car-t therapy. Another one of MedVax's drugs in clinic is MX-402 - a unique B-cell epitope HER-2 Peptide vaccine that had showed safety and strong signals of efficacy in an interim Phase I trial. Eight of twelve patients showed clinical benefit, with one patient in complete remission. MedVax's team is comprised of world renowned scientists and biotech industry professionals.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of MedVax Technologies, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For media inquiries, please contact:
VP, Business Development & Public Relations
MEDVAX TECHNOLOGIES, INC.
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: (617) 674-7718 ~ Fax: (617) 674-7701
Source: MedVax Technologies, Inc.